William Blair Has Negative Estimate for Enovis Q4 Earnings

Key Points

• William Blair has adjusted their Q4 2026 earnings per share (EPS) estimate for Enovis Corporation to $1.03, down from a previous forecast of $1.05.
• Several research firms, including Canaccord Genuity and JMP Securities, have lowered their price targets for Enovis, with the average target now around $51.00.
• Enovis reported a Q2 earnings beat with $0.79 EPS, surpassing the consensus estimate of $0.74, alongside a revenue of $564.50 million.

Enovis Corporation (NYSE:ENOV - Free Report) - Stock analysts at William Blair lowered their Q4 2026 earnings per share (EPS) estimates for Enovis in a research note issued to investors on Thursday, August 7th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $1.03 per share for the quarter, down from their prior estimate of $1.05. The consensus estimate for Enovis' current full-year earnings is $2.79 per share.

ENOV has been the topic of a number of other reports. Needham & Company LLC decreased their price objective on Enovis from $57.00 to $49.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group cut their target price on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company cut their target price on Enovis from $48.00 to $41.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Finally, UBS Group dropped their price objective on Enovis from $65.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Enovis presently has a consensus rating of "Buy" and an average price target of $51.00.

Enovis Trading Up 2.7%

ENOV stock traded up $0.77 during midday trading on Monday, reaching $29.59. 215,977 shares of the company traded hands, compared to its average volume of 1,198,763. Enovis has a 52-week low of $25.47 and a 52-week high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. The business has a 50 day moving average of $30.37 and a 200-day moving average of $34.80. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -2.08 and a beta of 1.70.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.05. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. The company had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. During the same period in the previous year, the business earned $0.62 earnings per share. The firm's revenue for the quarter was up 7.5% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC lifted its holdings in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares during the period. Farther Finance Advisors LLC lifted its holdings in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after buying an additional 536 shares during the period. Quarry LP lifted its holdings in shares of Enovis by 506.1% during the 4th quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after purchasing an additional 749 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Enovis by 144.8% during the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after purchasing an additional 692 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after purchasing an additional 707 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.